Want to take quizzes and track your credits?
In a 2020 phase 2 randomized clinical trial involving patients with neovascular age-related macular degeneration, the mean change in best-corrected visual acuity was no different in patients given intravitreal faricimab (an anti–angiopoietin-2 and anti–vascular endothelial growth factor A monoclonal antibody) every 12 or 16 weeks vs ranibizumab every 4 weeks. This video provides a detailed summary of the trial background, methods, and findings. Faricimab is under evaluation in phase 3 clinical trials for its efficacy and safety in a broader population of patients with neovascular age-related macular degeneration. Click the Related Article link for the full clinical report.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
You currently have no searches saved.
You currently have no courses saved.